2009
Safety and Efficacy of Drug-Eluting and Bare Metal Stents
Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 3198-3206. PMID: 19528338, DOI: 10.1161/circulationaha.108.826479.Peer-Reviewed Original ResearchConceptsBare metal stentsDrug-eluting stentsTarget vessel revascularizationMyocardial infarctionVessel revascularizationObservational studyMetal stentsEfficacy end pointTotal patientsOverall mortalityDrug-ElutingDES useLabel indicationsLabel useResidual confoundingBMS useRCTsPatientsDrug AdministrationInfarctionRevascularizationEnd pointMortality dataComparable reductionStents
2006
Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial. Journal Of Endovascular Therapy 2006, 13: 701-710. PMID: 17154704, DOI: 10.1583/05-1704.1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlloysAngioplasty, BalloonAnti-Bacterial AgentsAtherosclerosisBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleDouble-Blind MethodDrug CarriersFemaleFemoral ArteryHumansKaplan-Meier EstimateMaleMiddle AgedProspective StudiesProsthesis FailureRecurrenceSafetySirolimusStentsTreatment OutcomeConceptsChronic limb ischemiaAnkle-brachial indexBare stent groupRestenosis rateSirolimus groupLimb ischemiaStent groupSuperficial femoral artery occlusionType C lesionsDouble-blinded studySymptoms of claudicationBare nitinol stentsMajority of patientsSuperficial femoral arteryFemoral artery occlusionStent restenosis rateNitinol self-expanding stentsSelf-expanding stentsTypes of stentsTVR ratesTLR rateArtery occlusionC lesionsClinical outcomesDrug-Eluting